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physiological methods and validated questionnaires. Ten 
single nucleotide polymorphisms (SNPs) have previously been 
suggested to be predictive of late radiation induced toxicity 
by GWAS studies or candidate gene studies. The objective of 
this study was to test the ten SNPs in this unique cohort. The 
strength of the reportings as well as the clinical data 
available served as the rationale for using our rather small 
cohort as a validation cohort. 
Materials and Methods: The patients in this cohort have 
received EBRT 70-78 Gy for prostate cancer with curative 
intent. Functional toxicity endpoints have been examined by 
sigmoidoscopy, manometry, endoanal ultrasonography and 
impedance planimetry in an earlier study. Objective 
endpoints include the Vienna Rectoscopy Score (VRS), cross 
sectional area (CSA) of rectum at distension, maximum 
resting pressure (MRP) and maximum squeezing pressure 
(MSP) of anal sphincters. The subjective measure RT-
Anorectal dysfunction score (RT-ARD) was obtained from the 
questionnaires. Biological material from the patients in this 
cohort is available from an established research biobank. The 
SNPs were investigated in DNA from fibroblasts with TaqMan 
SNP assays. Statistical analyses was carried out with Stata13. 
For each SNP (table I) the reported risk allele was identified 
and due to the small sample size a risk-allele average was 
created for each patient. This risk-allele average was 
correlated to RT-ARD, VRS, MRP, MSP and CSA by Spearman's 
rank correlation. 
 
Results: All SNPs in the cohort were in Hardy-Weinberg 
equilibrium. Preliminary results showed no statistically 
significant correlations between the risk-allele average and 
toxicity end points tested. Spearman´s rank correlations ρ 
(rho) were as follows: VRS ρ = 0.17 p = 0.33, MRP ρ = -0.08 p 
= 0.64, MSP ρ = 0.02 p = 0.91, CSA ρ = 0.03 p = 0.88, RT-ARD 
ρ = -0.26 p = 0.13. 
Conclusions: Preliminary results indicate no correlation 
between risk-allele average and late radiation toxicity end 
points tested. The cohort will be expanded with 234 patients 
having received the same treatment and with the same 
questionnaire data on morbidity.  
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Purpose/Objective: Radiation-induced lung toxicity (RILT) 
varies significantly between patients at similar doses to the 
lung and can seriously affect the quality of life. The 
identification of prognostic biomarkers for radiation-induced 
toxicity is crucial for personalized RT: to select patients for 
proton therapy or dose escalation. We hypothesized variation 
in the mitochondrial genome (mtDNA) is a biomarker for 
RILT, since mitochondria and RT have several processes in 
common, among which reactive oxygen species (ROS) 
production. 
Materials and Methods: Blood DNA was isolated from 372 
(training set, Maastricht) and 68 (test set, Ghent) lung cancer 
patients. After exclusion of patients that had surgery, had 
other tumors within 5 years prior to lung cancer, received a 
palliative dose or for which baseline dyspnea score was 
unknown, 277 and 53 patients were remaining for the training 
and test set respectively. Baseline dyspnea (at the start of 
RT) and maximal dyspnea 3-6 months after RT were scored 
according to the CTCAE version 3.0 criteria. The endpoint of 
analysis was dyspnea grade>=2 after RT. Additionally, DNA 
was obtained from fibroblasts of 21 breast cancer patients for 
which the toxicity grade after radiotherapy was known 
(LENT/SOMA criteria). mtDNA was resequenced using 
mitochips and homoplasmic deviations from the revised 
Cambridge reference sequence were recorded. Variants were 
classified into 7 functional categories based on their 
theoretical effect on OXPHOS function. 
Results: Using the 7 functional categories as input features, 
logistic regression analysis corrected for baseline dyspnea 
score resulted in an AUC of 0.78 for the training set, which 
was significantly better than the current international gold 
standard Mean Lung Dose (AUC 0.57; p < 0.001). The AUC for 
the test set was 0.66 but the power of the validation was 
limited due to the small sample size. Validation in a second 
external test set is ongoing. Additionally, using mtDNA 
variation data we were able to classify breast cancer patients 
in the correct toxicity group with 80% accuracy. 
Conclusions: Our data showed that mtDNA variation is a 
valuable biomarker for RILT. Furthermore, we have 
preliminary data in breast cancer patients that the predictive 
effect of mtDNA might be applicable to radiation toxicity in 
general. 
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Purpose/Objective: (1) To quantify the geometric and 
dosimetric variability of prostate contouring on US for low-
dose-rate brachytherapy. (2) To assess the dosimetric 
variability of registrations of T1-weighted MRI with C-arm 
cone beam CT (CBCT) and the currently performed US-CBCT 
registrations. 
Materials and Methods: VariSeed studies of eleven patients 
previously treated with low-dose-rate brachytherapy at our 
institute were enrolled in a multi-observer study. Six 
observers performed three sessions of prostate contouring on 
US and registrations of US- and MRI-CBCT. 
Prostate contours were sampled at 10 degree increments of 
the polar and azimuthal angles from the center of mass. The 
